Tissue Repair Limited (ASX: TRP) has resumed direct distribution and management of TR Pro+ in the aesthetic channel across Australia and New Zealand. The move sits alongside the Company’s existing distribution of TR Pro+ in the medical channel.
Announced on 2 September 2026, the change reverses the September 2025 appointment of Advanced Cosmeceuticals Pty Ltd as Tissue Repair’s distributor, marking a return to a direct distribution model in the aesthetic market.
What the transition involves
Tissue Repair is transitioning customer relationships, ordering and account management back in-house. The Company has stated it does not currently anticipate any interruption to customers’ ability to order TR Pro+ during the transition.
Under the new arrangement, Tissue Repair will directly assume responsibility for:
-
Customer relationships
-
Sales
-
Ordering
-
Account management
-
Customer engagement across business development opportunities, promotions, and education
Bringing distribution in-house gives the Company direct ownership of the customer relationship and margin, positioning it for the next stage of the aesthetic channel’s development.
When big ASX news breaks, our subscribers know first
What TR Pro+ is and why the channel matters
TR Pro+ is Tissue Repair’s proprietary hydrogel designed for use following aesthetic procedures and in the management of acute wounds. A hydrogel is a water-based dressing applied to skin to support healing. The product is listed on the Australian Register of Therapeutic Goods (ARTG), the register maintained by Australia’s medicines and medical devices regulator.
The announcement references two distinct channels. The aesthetic channel covers use following cosmetic and aesthetic procedures, while the medical channel covers clinical wound management settings.
For a small-cap company, a direct distribution model can matter in several ways. It brings the business closer to its customers, retains margin that would otherwise be shared with a distributor, and gives the Company greater control over product education and promotion.
Direct control over an ARTG-listed proprietary product in a growing aesthetic market strengthens the Company’s grip on its commercial pathway.
Management commentary
Tony Charara, CEO, Tissue Repair
“Advanced Cosmeceuticals has been Tissue Repair’s distribution partner in the Australian and New Zealand aesthetic market since September 2025.
“Tissue Repair has determined that returning to a direct distribution model is the appropriate approach for the next stage of development of the TR Pro+® business.
“Our immediate priority is to ensure continuity for existing customers and a smooth transition of customer relationships and ordering arrangements. We look forward to engaging directly with our customers and supporting the continued development of the TR Pro+® business.”
What comes next for investors
Tissue Repair has stated it will provide further updates regarding the transition and the development of the TR Pro+ business as appropriate.
The shift signals the Company is investing in owning its commercial engine as it prepares for the next stage of the aesthetic channel’s development. The table below summarises the key changes.
| Element | Previous Arrangement | New Arrangement |
|---|---|---|
| Aesthetic channel distribution | Advanced Cosmeceuticals (from Sept 2025) | Tissue Repair (direct) |
| Customer relationships & ordering | Distributor-managed | Tissue Repair-managed |
| Medical channel | Existing distribution | Existing distribution (unchanged) |
Don’t Miss the Next Healthcare Breakout
Get FREE breaking ASX healthcare news delivered to your inbox within minutes of release, complete with in-depth analysis. Join 20,000+ investors already staying ahead of the market with Big News Blast. Click the “Free Alerts” button to receive real-time alerts the moment market-moving healthcare announcements hit the ASX.